Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count

HIV Medicine

Volumn 9, Issue 1, 2008, Pages 14-18

  Knobel, Hernando ^a   Guelar, A ^a   Montero, M ^a   Carmona, A ^a   Luque, S ^a   Berenguer, N ^a   Gonzalez A ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Adverse events; Hepatotoxicity; Nevirapine; Rash

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG ERUPTION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INTERSTITIAL NEPHRITIS; LIVER TOXICITY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYOCARDITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEX FACTORS;

EID: 38349145563     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00513.x     Document Type: Article

References (21)

1. Podzamcer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Expert Opin Pharmacother 2001; 2: 2065-2078.
2. Stern JO, Robinson PA, Love J, Lane S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J AIDS 2003; 34: S22-S33.
3. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J AIDS 2004; 35: 538-539.
4. Boehringer Ingelheim GmbH. Viramune® (nevirapine) tablets and Viramune® (nevirapine) oral suspension [package insert]. 2007.
5. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection, 2006 recommendations of the international AIDS society-USA panel. JAMA 2006; 296: 827-843.
6. Iribarren JA, Labarga P, Rubio R et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana. Enferm Infecc Microbiol Clin 2004; 22: 564-642.
7. van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19: 463-471.
8. Mocroft A, Staszewski S, Weber R et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced HIV-infected patients with high and low CD4+ T-cell counts. Antiviral Ther 2007; 12: 325-333.
9. Knobel H, MiróJM, Mahillo B et al. Failure of cetirizine to prevent nevirapine-associated rash. A double-blind placebo-controlled trial for the GESIDA 26/01 study. J AIDS 2004; 37: 1276-1281.
10. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-1092.
11. Ho TT, Wong KH, Chan KC, Lee SS. High incidence of nevirapine-associated rash among HIV-infected Chinese. AIDS 1998; 12: 2082-2083.
12. Ananworanich J, Moor Z, Siangphoe U et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19: 185-192.
13. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennet C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J AIDS 2004; 35: 120-125.
14. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.
15. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
16. Bonjoch A, Paredes R, Domingo P et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-329.
17. Wolf E, Koegl C, Theobald T. Nevirapine-associated hepatotoxicity: No increased risk for females or high CD4 count in a single centre HIV cohort. In Program of Abstracts 46th ICAAC, San Francisco, CA, September 27-30, 2006 [Abstract H-1063].
18. De Lazzari E, Leon A, Arnaiz JA et al. Risk of hepatotoxicity in virologically suppressed HIV patients switching to nevirapine according to gender and CD4 count. In Program of Abstracts 46th ICAAC, San Francisco, CA, September 27-30, 2006 [Abstract H-1064].
19. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: No link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250cells/μL. AIDS 2006; 20: 2233-2236.
20. Phillips E, Gutiérrez S, Jahnke N et al. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. AIDS 2007; 21: 1561-1568.
21. Martin AM, Nolan D, James I et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 *0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19: 97-99.